T1	Participants 234 255	children with autism.
T2	Participants 451 639	risperidone in children ages 5 to 17 years with autism accompanied by severe tantrums, aggression, and/or self-injurious behavior who showed a positive response in an earlier 8-week trial.
T3	Participants 997 1025	Part I included 63 children.
T4	Participants 1377 1406	Part II included 32 patients.
T5	Participants 1663 1754	children with autism characterized by tantrums, aggression, and/or self-injurious behavior.
